Imeik Technology DevelopmentLtd Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Imeik Technology DevelopmentLtd has been growing earnings at an average annual rate of 34.9%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 34.1% per year. Imeik Technology DevelopmentLtd's return on equity is 26.7%, and it has net margins of 65.9%.
Belangrijke informatie
34.9%
Groei van de winst
32.1%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.3% |
| Inkomstengroei | 34.1% |
| Rendement op eigen vermogen | 26.7% |
| Nettomarge | 65.9% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Imeik Technology Development Co.,Ltd. (SZSE:300896) Just Missed Earnings: Here's What Analysts Think Will Happen Next
Oct 26
Investors Appear Satisfied With Imeik Technology Development Co.,Ltd.'s (SZSE:300896) Prospects As Shares Rocket 43%
Sep 27Are Investors Undervaluing Imeik Technology Development Co.,Ltd. (SZSE:300896) By 47%?
Jul 02Why Investors Shouldn't Be Surprised By Imeik Technology Development Co.,Ltd.'s (SZSE:300896) P/E
Feb 29Opbrengsten en kosten
Hoe Imeik Technology DevelopmentLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 3,075 | 2,026 | 376 | 278 |
| 30 Jun 24 | 3,067 | 2,016 | 383 | 272 |
| 31 Mar 24 | 3,047 | 1,972 | 390 | 264 |
| 31 Dec 23 | 2,869 | 1,858 | 409 | 250 |
| 30 Sep 23 | 2,620 | 1,695 | 422 | 217 |
| 30 Jun 23 | 2,513 | 1,642 | 398 | 213 |
| 31 Mar 23 | 2,138 | 1,404 | 332 | 188 |
| 01 Jan 23 | 1,939 | 1,264 | 291 | 173 |
| 30 Sep 22 | 1,914 | 1,236 | 276 | 156 |
| 30 Jun 22 | 1,699 | 1,118 | 258 | 123 |
| 31 Mar 22 | 1,619 | 1,061 | 258 | 108 |
| 01 Jan 22 | 1,448 | 958 | 221 | 102 |
| 30 Sep 21 | 1,268 | 858 | 189 | 90 |
| 30 Jun 21 | 1,101 | 718 | 164 | 85 |
| 31 Mar 21 | 889 | 567 | 134 | 78 |
| 31 Dec 20 | 709 | 440 | 114 | 62 |
| 30 Sep 20 | 627 | 376 | 113 | 51 |
| 31 Dec 19 | 558 | 306 | 126 | 49 |
| 31 Dec 18 | 321 | 123 | 107 | 34 |
| 31 Dec 17 | 222 | 82 | 68 | 28 |
| 31 Dec 16 | 141 | 53 | 60 | 0 |
| 31 Dec 15 | 112 | 18 | 74 | 0 |
| 31 Dec 14 | 75 | 28 | 36 | 0 |
Kwaliteitswinsten: 300896 has high quality earnings.
Groeiende winstmarge: 300896's current net profit margins (65.9%) are higher than last year (64.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 300896's earnings have grown significantly by 34.9% per year over the past 5 years.
Versnelling van de groei: 300896's earnings growth over the past year (19.5%) is below its 5-year average (34.9% per year).
Winst versus industrie: 300896 earnings growth over the past year (19.5%) exceeded the Biotechs industry 0.08%.
Rendement op eigen vermogen
Hoge ROE: 300896's Return on Equity (26.7%) is considered high.